Banco Santander, S.A. Press Releases

SAN 
$7.19
*  
0.01
0.14%
Get SAN Alerts
*Delayed - data as of Mar. 5, 2015  -  Find a broker to begin trading SAN now
Exchange: NYSE

Community Rating:
View:    SAN After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Santander Would Maintain Capital Strength In Severely Adverse Scenario, Based On Federal Reserve Stress Test
3/5/2015 5:20:00 PM - PR Newswire


Santander names Scott Powell CEO of Santander Holdings USA, Inc.
3/2/2015 9:59:00 AM - PR Newswire


Toujeo® Receives Positive Opinion from the European Regulatory Authorities
2/27/2015 7:16:00 AM - GlobeNewswire


Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®
2/25/2015 8:25:00 PM - PR Newswire


Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®
2/25/2015 8:02:00 PM - GlobeNewswire


Santander Announces New Account Opening Screening Process
2/20/2015 10:43:00 AM - PR Newswire


Reality TV Star and Acclaimed Regional Mexican Female Artist Chiquis Rivera Hosts Dress Cutting Event in Miami
2/19/2015 5:36:00 PM - PR Newswire


ENGAGE Randomized Clinical Trial Evaluating Cerdelga® (eliglustat) for Treatment-Naïve Patients with Gaucher Disease Type 1 Published in The Journal of the American Medical Association
2/17/2015 11:31:00 AM - Business Wire


Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network’s WORLD Symposium 2015
2/12/2015 4:15:00 PM - Business Wire


Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Network’s WORLD Symposium 2015
2/12/2015 8:45:00 AM - Business Wire


Sanofi Delivers Business EPS Growth of 7.3% at CER in 2014
2/5/2015 7:49:00 AM - PR Newswire


Sanofi FY 2014 - Interview With Chairman & CEO Serge Weinberg
2/5/2015 2:14:00 AM - PR Newswire


Sanofi: Sanofi delivers Business EPS(1) growth of 7.3% at CER in 2014
2/5/2015 1:48:00 AM - GlobeNewswire


Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
2/3/2015 7:00:00 AM - PR Newswire


Sanofi : Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S.
2/3/2015 1:00:00 AM - GlobeNewswire


Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
1/26/2015 1:00:00 AM - PR Newswire


European Commission Grants Marketing Authorization for Cerdelga® (eliglustat), Genzyme’s Oral Therapy for Gaucher Disease Type 1
1/22/2015 1:00:00 AM - Business Wire


Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
1/21/2015 2:47:00 PM - PR Newswire


100,000 Strong in the Americas Innovation Fund Grant Competition Opens Today with Support from Santander
1/15/2015 3:21:00 PM - PR Newswire
▲3.45 % Price Change since this news event. The Volume Ratio is 0.57.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA
1/12/2015 1:00:00 AM - PR Newswire


D. E. Shaw Renewable Investments Announces Groundbreaking of Red Horse 2 Wind and Solar Project
1/9/2015 3:10:00 PM - Business Wire
▲3.16 % Price Change since this news event. The Volume Ratio is 2.16.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia
1/9/2015 1:00:00 AM - PR Newswire


Santander Bank, N.A. Announces Pricing of Private Placement of Senior Notes
1/7/2015 6:14:00 PM - PR Newswire
▼-10.68 % Price Change since this news event. The Volume Ratio is 5.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Santander Bank, N.A., Announces Launch of Private Placement of Senior Notes
1/7/2015 10:15:00 AM - PR Newswire
▼-8.41 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol
12/15/2014 8:00:00 AM - PR Newswire